1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
bioMérieux S.A.

bioMérieux S.A.

BMXXY
bioMérieux S.A.US flagOther OTC
8.23
USD
+0.04
- -
9.71BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
1.34
1.44
1.66
1.78
1.94
2.06
2.26
2.64
2.85
3.04
3.11
3.38
3.45
Basic EPS, GAAP
0.14
0.11
0.09
0.15
0.2
0.22
0.23
0.34
0.51
0.38
0.3
0.37
0.34
Free Cash Flow per Basic Share
0.09
0.12
0.09
0.09
0.29
0.15
0.11
0.26
0.45
0.16
0.09
0.27
0.38
Dividend per Share
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.06
0.09
0.08
0.09
0.09
Book Value per Share
0.15
0.12
0.1
0.16
0.21
0.23
0.24
0.35
0.52
0.39
0.31
0.38
0.35
Tangible Book Value per Share
0.69
0.41
0.48
0.56
0.73
0.74
0.92
1.2
1.76
1.87
2.14
2.54
2.52
Basic Weighted Avg Shares
1,185
1,183
1,184
1,180
1,179
1,178
1,183
1,181
1,183
1,179
1,182
1,178
1,180
Sales/Revenue/Turnover
1,588
1,698
1,965
2,103
2,288
2,421
2,675
3,118
3,376
3,589
3,675
3,980
4,070
Operating Margin (%)
16.52
13.35
13.23
14.16
14.63
15.02
13.85
19.64
25
17.43
15.48
16.03
17.07
Depreciation Expense
91
105
120
143
140
177
190
211
248
248
259
302
307
Net Income, GAAP
164
135
110
179
238
256
273
404
601
452
358
432
398
Effective Tax Rate (%)
32.2
27.57
37.32
30.78
18.63
20.31
22.4
23.17
22.67
24.13
26.17
26.64
24.5
Profit Margin (%)
10.35
7.94
5.62
8.52
10.41
10.59
10.2
12.97
17.8
12.61
9.73
10.86
9.77
Working Capital
731
416
413
423
630
518
268
738
1,237
1,086
1,118
1,367
1,476
LT Debt
305
306
309
365
391
525
154
352
363
318
355
349
330
Total Equity
1,267
1,389
1,503
1,621
1,737
2,002
2,255
2,481
3,164
3,643
3,752
4,211
4,106
Return on Invested Capital (%)
10.95
8.75
8.1
9.32
11.45
10.79
9.47
14.62
17.96
11.18
9.16
9.55
10.35
Return on Capital (%)
39.11
26.11
23.71
33.28
36.93
31.89
30.46
45.34
58.9
43.77
42.6
49.32
45.17
Return on Common Equity (%)
101.83
83.48
82.03
114.22
107.93
98.9
98.59
115.35
116.78
83.97
85.76
106.22
93.12

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.84%
11.08%
-2.49%
Free Cash Flow
49.61%
41.66%
40.93%
Net Income, GAAP
17.31%
3.16%
-8.03%
Sales/Revenue/Turnover
7.63%
5.51%
2.26%
Total Cash Common Dividend
- -
- -
5.89%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3,675
2024
- -
- -
- -
- -
3,980
2025
- -
- -
- -
- -
4,070

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.3
2024
- -
- -
- -
- -
0.37
2025
- -
- -
- -
- -
0.34

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.08
2024
- -
- -
- -
- -
0.09
2025
- -
- -
- -
- -
0.09

Company Description

APIChatGPT
CEO
Pierre Boulud
Full Time Employees
14,147
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
376 Chemin De l’Orme Marcy l'Étoile ARA France 69280
IPO Date
Jun 9, 2023
Website
biomerieux.com
Similar Companies
FALCO HOLDINGS Co., Ltd. (4671.T)
China Holdings, Inc. (CHHL)
Microba Life Sciences Limited (MAP.AX)
Invitae Corporation (NVTAQ)
Genetic Signatures Limited (GSS.AX)
Longduoduo Company Limited (LDDD)
Business
bioMérieux S.A. is a French multinational biotechnology company specializing in the development, manufacture, and marketing of in vitro diagnostic solutions primarily for infectious diseases. Founded in 1963 and headquartered in Marcy-l'Étoile, France, the company operates globally across more than 44 countries and serves over 160 countries through direct sales and a broad distributor network. bioMérieux's core products include diagnostic systems, reagents, instruments, software, and services aimed at clinical microbiology, molecular biology, immunoassays, and industrial microbiological control. These products are used for diagnosing infectious diseases such as HIV and tuberculosis, cancer screening, monitoring cardiovascular emergencies, and ensuring consumer safety in food, pharmaceutical, and cosmetic products. The company also provides solutions for veterinary diagnostics, blood banks, and antimicrobial stewardship, emphasizing rapid diagnostics and food safety sectors. Recent major developments for bioMérieux include the acquisition of Neoprospecta in early 2025, expanding its data and genomics offerings especially in Brazil and Latin America, reinforcing its augmented diagnostics approach. In 2024, bioMérieux acquired Canadian software company LUMED to enhance its clinical decision support system capabilities for antimicrobial prescriptions and healthcare-associated infection monitoring. The company also completed the acquisition of SpinChip in late 2025, targeting expansion in the point-of-care diagnostics market with innovative lab-quality rapid tests. Additional product innovations were introduced including new panels under the BIOFIRE® brand, targeting gastrointestinal pathogens and real-time microbial trend analysis. The company reinforces its strategic growth through these acquisitions and innovations aligned with its GO- 28 strategic plan, focusing on expanding clinical and industrial diagnostic solutions. bioMérieux operates primarily in the biotechnology and life sciences industry, targeting hospitals, clinical labs, pharmaceutical and food industries, as well as veterinary diagnostic labs. It is a family-controlled public company listed on Euronext Paris under the ticker BMXXY. Through its subsidiaries and a focus on continuous innovation, bioMérieux maintains an influential global presence in infectious disease diagnostics, molecular testing, and microbial detection technologies with an expanding footprint in emerging markets and new diagnostic software solutions.

Company News

APIChatGPT

  • seekingalpha.com

    bioMérieux S.A. (BMXXY) Analyst/Investor Day Transcript